Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Non-Current Assets came in at $227.5 million in Q2 2026, down 5.55% YoY from $240.8 million in Q2 2025, and down 1.57% on a QoQ basis from $231.1 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Non-Current Assets data on file, last reported at $227.5 million in Q2 2026.
- Quarterly Non-Current Assets fell 5.55% year-over-year to $227.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $931.8 million (down 4.62% YoY) and the FY2025 annual result came in at $236.5 million, down 4.94% from the prior year.
- Non-Current Assets slipped to $227.5 million in Q2 2026, from $231.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $250.0 million in Q4 2023 to a low of $30.6 million in Q2 2022.
- A 5-year average of $212.4 million and a median of $236.6 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 10.93% — and 2023, when it soared 677.77%.
- Tracing KNSA's Non-Current Assets over 5 years: stood at $216.6 million in 2022, then increased by 15.43% to $250.0 million in 2023, then retreated by 0.51% to $248.8 million in 2024, then retreated by 4.94% to $236.5 million in 2025, then dropped by 3.8% to $227.5 million in 2026.
- The last three Non-Current Assets figures came in at $227.5 million (Q2 2026), $231.1 million (Q1 2026), and $236.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Kiniksa Pharmaceuticals International | 6.08 Bn | 5.56 Bn | 220.03 Mn | 227.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 227.48 Mn |
| Mar 31, 2026 | 231.11 Mn |
| Dec 31, 2025 | 236.46 Mn |
| Sep 30, 2025 | 236.80 Mn |
| Jun 30, 2025 | 240.84 Mn |
| Mar 31, 2025 | 243.42 Mn |
| Dec 31, 2024 | 248.75 Mn |
| Sep 30, 2024 | 244.00 Mn |
| Jun 30, 2024 | 241.41 Mn |
| Mar 31, 2024 | 249.08 Mn |
| Dec 31, 2023 | 250.03 Mn |
| Sep 30, 2023 | 226.95 Mn |
| Jun 30, 2023 | 238.29 Mn |
| Mar 31, 2023 | 211.36 Mn |
| Dec 31, 2022 | 216.61 Mn |
| Sep 30, 2022 | 218.14 Mn |
| Jun 30, 2022 | 30.64 Mn |
| Mar 31, 2022 | 32.21 Mn |
| Dec 31, 2021 | 36.35 Mn |
| Sep 30, 2021 | 35.35 Mn |